AlphAIAlphAI — Financial news for AI agents
tradingview.comAUG 242 min read$KROS

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros Therapeutics (KROS) reported a Q2 2026 loss of $1.45 per share, wider than estimates, with revenues falling to zero. The company's focus is on rinvatercept, with clinical trials ongoing. KROS has $257.6M in cash, expected to last until mid-2028. Shares have dropped 46.8% YTD, trading at 37.1X forward sales.

Original reporting
tradingview.com
Published Aug 24, 2026, 4:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? — source image
Source · tradingview.com
Decision brief

The 30-second read

$KROSBearishLow
01

Why it matters

Earnings miss likely pressures the stock further; investors may wait for Phase II data.

02

Market read

Earnings disappointment for a micro‑cap biotech with limited cash runway.

03

What to watch

Cash runway to 2028 and potential Takeda partnership cost reductions may mitigate risk.

Relevance 6/10Novelty 6/10Timing: post‑quarter earnings release

Background

Keros Therapeutics reports a Q2 loss with zero revenue, emphasizing pipeline risk.

Company-level read

Ticker impact

$KROSBearishMedium confidence
Context

Q2 2026 earnings report shows a loss of $1.45 per share and zero revenue, a material new disclosure for the company.

Expected impact

Potential further price decline as investors reassess valuation.

Evidence & confidence

The loss exceeds consensus and revenue fell to zero, reducing near-term confidence.

Market effects

Sector

Highlights revenue volatility in biotech firms reliant on collaboration income.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

If rinvatercept data prove compelling, the stock could rebound despite current losses.

Key entities

  • company
    Keros Therapeutics

    Biotech firm developing rinvatercept.

Read at source← All news

Related articles

SEP 28
$KROSMedAI 8/10

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD • Initial data expected in the first half of 2027 LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: K

SEC EDGAR 8-K2 min
SEP 28
$BYDMed

Boyd Gaming stock hits 52-week low at 69.81 USD

Boyd Gaming Corp's stock hit a 52-week low at $69.81, down 19.6% over the past year. The company's P/E ratio is 3.04, and it is considered undervalued by InvestingPro. Boyd Gaming's Q2 earnings slightly beat expectations with $1.93 EPS, but revenue of $1.03 billion missed forecasts. Analysts Mizuho and Stifel raised their price targets to $104 and $92, respectively, while Goldman Sachs noted a slowdown in regional casino revenues.

uk.investing.com2 min
SEP 28
Med

TotalEnergies targets 20% annual power generation growth through 2030

TotalEnergies targets 4% annual energy production growth through 2030, with oil and gas up 3% and electricity up 20%. It aims to cut emissions 50% by 2030. Free cash flow is expected to rise $10B, $4 per share, by 2030. Beyond 2030, it plans 2-3% oil/gas and 10-12TWh electricity growth annually, investing $14-17B yearly.

trend.az2 min
SEP 28
$ZBAOMed

Zhibao Technology Inc. (ZBAO): Financial results for H2 2000

Zhibao Technology Inc. (ZBAO) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 Merger and Acquisition Agreement Seller Name: CHOI SAI WAI (the “Seller”), the sole shareholder of the Target Company Address: SSMOSENTRAL, NO. 7, JALAN STESEN SENTRAL 5, KUALA LUMPUR SENTRAL, 50623 KUALA LUMPUR. Purchaser Name: Zhibao Technology Inc. (the “Purchaser

SEC EDGAR 6-K2 min
SEP 28
$GNSMed

Genius Group Ltd (GNS): Financial results for H1 2026

Genius Group Ltd (GNS) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Genius Group Announces 140% Increase in Revenue, $6.4 Million Net Profit from Operating Units, 79% Reduction in Total Net Loss in First Half of 2026 188% increase in Gross Profit, growth in net assets to $106 million Company restructure in H1 2026 has resulted in pro

SEC EDGAR 6-K2 min